At the time of writing, Transmedics Group Inc [TMDX] stock is trading at $123.34, up 1.67%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TMDX shares have gain 1.26% over the last week, with a monthly amount glided 33.70%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on December 17, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $75 from $116. Previously, Needham downgraded its rating to Hold on November 22, 2024. On October 29, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $125 on the stock. Needham reiterated its Buy rating and decreased its price target to $109 on October 29, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $200 as its price target on September 24, 2024. Needham started tracking with a Buy rating for this stock on August 21, 2024, and assigned it a price target of $208. In a note dated June 06, 2024, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $161 on this stock.
For the past year, the stock price of Transmedics Group Inc fluctuated between $55.00 and $177.37. Currently, Wall Street analysts expect the stock to reach $105 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $123.34 at the most recent close of the market. An investor can expect a potential drop of -14.87% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
According to Transmedics Group Inc [NASDAQ:TMDX], the company’s sales were 488.23M for trailing twelve months, which represents an 48.21% jump. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.11%, Pretax Profit Margin comes in at 0.1%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.22 and Total Capital is 0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.95.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Transmedics Group Inc [NASDAQ:TMDX] has a current ratio of 9.10. In addition, the Quick Ratio stands at 8.32 and the Cash Ratio stands at 5.58. Considering the valuation of this stock, the price to sales ratio is 8.55, the price to book ratio is 15.67 and price to earnings (TTM) ratio is 90.65.
Transactions by insiders
Recent insider trading involved Basile Edward M, Director, that happened on May 09 ’25 when 6000.0 shares were sold. Director, EDWARD BASILE completed a deal on May 09 ’25 to buy 6000.0 shares. Meanwhile, Chief Commercial Officer Khayal Tamer I sold 2407.0 shares on Mar 03 ’25.
